Sangamo Therapeutics shares are trading higher. HC Wainwright & Co. reiterated a Buy rating on the stock.
Portfolio Pulse from Benzinga Newsdesk
Sangamo Therapeutics shares are experiencing an uptick in trading following HC Wainwright & Co.'s decision to reiterate a Buy rating on the stock.
October 23, 2024 | 1:16 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Sangamo Therapeutics shares are trading higher after HC Wainwright & Co. reiterated a Buy rating, indicating positive sentiment from analysts.
The reiteration of a Buy rating by HC Wainwright & Co. suggests confidence in Sangamo Therapeutics' future performance, likely boosting investor sentiment and driving the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100